Published in Vaccine Weekly, June 29th, 1998
The data was presented at the Annual Meeting of the American Diabetes Association (ADA) in Chicago, Illinois. Anergen anticipates that Phase I clinical (safety) trials of the compound, DiavaX, will be initiated within a year.
In the study, Anergen scientists treated NOD mice before development of diabetes symptoms (5 weeks) or after the onset of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly